Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
ACS Applied Materials & Interfaces|December 23, 2020
Hyaluronan-Conjugated Carbon Quantum Dots for Bioimaging UseBedia Begüm Karakoçak, Amine Laradji, Tina Primeau, et al.
Journal of Medicinal Chemistry|December 13, 2021
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer ProgressionVishnu C Damalanka, Jorine J L P Voss, Matthew W Mahoney, et al.
Immunologic Research|August 18, 2005
Applications of major histocompatibility complex class I molecules expressed as single chainsTina Primeau, Nancy B Myers, Y Y Lawrence Yu, et al.
The Journal of Biological Chemistry|May 7, 2003
Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptideLonnie Lybarger, Y Y Lawrence Yu, Michael J Miley, et al.
Nature Communications|May 20, 2021
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancerNindo B Punturi, Sinem Seker, Vaishnavi Devarakonda, et al.
The Journal of Biological Chemistry|November 17, 2022
Diptoindonesin G is a middle domain HSP90 modulator for cancer treatmentKristine Donahue, Haibo Xie, Miyang Li, et al.
Molecular Pharmaceutics|August 2, 2019
Folate Receptor α-Targeted <sup>89</sup>Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast CancerGyu Seong Heo, Lisa Detering, Hannah P Luehmann, et al.
Cancers|December 29, 2020
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft ModelsZhanfang Guo, Tina Primeau, Jingqin Luo, et al.
Molecular Cancer Therapeutics|December 7, 2018
Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast CancerShuying Liu, Shunqiang Li, Bailiang Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2015
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast CancerSuzanne E Wardell, Matthew J Ellis, Holly M Alley, et al.
Pageof 2